Integrated Filing — IndAS



General information about company

Scrip Code 500087
NSE Symbol CIPLA
MSEI Symbol NOTLISTED
ISIN INE059A01026
Name of company CIPLA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 13-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 31-03-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 13-05-2026   09:45:00
End date and time of board meeting 13-05-2026   13:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 23-01-2026
Indicate Company website link for updated RPT policy of the Company https://www.cipla.com/sites/default/files/2026-02/Policy-on-Related-party-transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 4,20,998.00 18,97,995.00
Other income 18,022.00 1,12,265.00
Total income 4,39,020.00 20,10,260.00
2 Expenses
(a) Cost of materials consumed 96,558.00 3,99,234.00
(b) Purchases of stock-in-trade 76,351.00 2,58,797.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (35,287.00) (59,645.00)
(d) Employee benefit expense 86,924.00 3,35,048.00
(e) Finance costs 674.00 1,930.00
(f) Depreciation, depletion and amortisation expense 21,811.00 65,843.00
(f) Other Expenses
1 Other Expenses 1,36,641.00 5,17,922.00
2 Impairment of investment in associates 3,100.00 3,100.00
Total other expenses 1,39,741.00 5,21,022.00
Total expenses 3,86,772.00 15,22,229.00
3 Total profit before exceptional items and tax 52,248.00 4,88,031.00
4 Exceptional items 0.00 (24,437.00)
5 Total profit before tax 52,248.00 4,63,594.00
6 Tax expense
7 Current tax 11,977.00 1,10,190.00
8 Deferred tax 1,807.00 1,886.00
9 Total tax expenses 13,784.00 1,12,076.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 38,464.00 3,51,518.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 38,464.00 3,51,518.00
17 Other comprehensive income net of taxes (5,538.00) (14,630.00)
18 Total Comprehensive Income for the period 32,926.00 3,36,888.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 16,156.00 16,156.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 34,03,955.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.76 43.52
Diluted earnings (loss) per share from continuing operations 4.76 43.49
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.76 43.52
Diluted earnings (loss) per share from continuing and discontinued operations 4.76 43.49
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The National Pharmaceutical Pricing Authority (“NPPA”) issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 (“DPCO”). In 1999 and 2000, the Company filed writ petitions before the Hon’ble Bombay High Court (“Bombay HC”) challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon’ble Supreme Court (“SC”). On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC’s Judgment the Company deposited an amount of Rs.175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003. Post 2003, the Company continued to receive demands (“Subsequent demands”) alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) take on record the NPPA/ Government of India’s RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC’s TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands. The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further. Without prejudice to the Company’s position of no amount being due towards the alleged overcharge (principal) or consequential interest, on 15th July 2025 the Company has voluntarily deposited with the NPPA an additional amount of Rs 27.07 Crores towards the principal against certain demand notices. The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to Rs 2,011 Crores with the principal of Rs 863 Crores and interest of Rs 1,148 Crores. The above demand notices do not include certain demand notices, jointly addressed to Okasa Pharma Private Limited or Okasa Limited (related parties and promoter group companies, collectively “Okasa), and the Company. These pertain to products manufactured by Okasa and marketed by Cipla. The Company responded to these demand notices (amounting to Rs 9.96 Crores), stating that it is not the manufacturer and therefore not liable. These demand notices are also subject matter under Business Transfer Agreement between Okasa and Cipla’s subsidiary which excludes the DPCO liability as part of the business transferred by Okasa to the subsidiary. Further, Okasa has independently challenged these demand notices before the Hon’ble Bombay HC. The Company has been legally advised that it expects a favourable outcome in respect of these matters and therefore no provision is considered necessary in respect of the aforementioned demand notices received till date including demand notices addressed singly/ jointly w.r.t transactions with Okasa. 3. The paid-up equity share capital stands increased to Rs 161.56 Crores (80,77,82,631 equity shares of face value Rs 2 each) upon allotment of 8,384 equity shares and 2,449 equity shares of Rs 2 each pursuant to ESOS 2013-A and “Cipla ESAR Scheme 2021” respectively during the quarter ended 31st March, 2026 4. The figures for the quarter ended 31st March, 2026 and 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. 5. Other income for the quarter ended 31st December, 2025 includes Rs. 200.01 Crores, dividend received from a subsidiary company. 6. Exceptional items for the quarter and year ended 31st March, 2025, represents Rs 294.66 Crores with respect to reversal of impairment loss recognized in earlier years for the investment in the wholly owned subsidiary, Cipla Pharma and Life Sciences Limited. 7. Effective 21st November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 244.37 Crores primarily arising due to change in definition of “wages” for employees and contract labours. Considering the materiality and non-recurring nature of this impact, the Company has presented such incremental impact under “Exceptional Item” in the standalone financial results for the quarter ended 31st December, 2025 and year ended 31st March, 2026. 8. During the quarter and year ended 31st March, 2026, the Company has recorded an impairment of Rs 31.00 Crores in the financial results in respect of an associate, on account of change in certain business conditions and market dynamics. 9. The Board in its meeting held on 19th March, 2026, has approved the scheme of amalgamation between Cipla Limited (“Transferee Company”) and its wholly owned subsidiary company Inzpera Healthsciences Limited (“Transferor Company”). The Scheme of Amalgamation is subject to necessary approvals required under the Companies Act, 2013, including approval of the Hon’ble National Company Law Tribunal, Mumbai. The Company is in the process of filing the Scheme with the authorities. 10. The figures of the previous year/periods have been regrouped/recast to render them comparable with the figures of the current period/year. 11. The Board of Directors of the Company at its meeting held on 13th May, 2026 has recommended a final dividend of Rs 13/- per equity share (face value of Rs. 2 each) for the financial year ended 31st March, 2026. The dividend is subject to approval of the shareholders at the ensuing annual general meeting of the Company. 12. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 13th May, 2026. These results have been subjected to audit by statutory auditors who have expressed an unqualified opinion.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3,78,245.00
Capital work-in-progress 72,023.00
Investment property 151.00
Goodwill 0.00
Other intangible assets 1,40,985.00
Intangible assets under development 25,736.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 10,84,789.00
Trade receivables, non-current
Loans, non-current 1,41,010.00
Other non-current financial assets
1 Other financial assets 1,17,484.00
Total of other non-current financial assets 1,17,484.00
Total non-current financial assets 13,43,283.00
Deferred tax assets (net) 5,023.00
Other non-current assets
1 Non-Current Tax Assets 47,386.00
2 Other non-current assets 45,275.00
Total of other non-current assets 92,661.00
Total non-current assets 20,58,107.00
2 Current assets
Inventories 4,35,371.00
Current financial asset
Current investments 6,76,844.00
Trade receivables, current 3,39,674.00
Cash and cash equivalents 24,880.00
Bank balance other than cash and cash equivalents 26,980.00
Loans, current 42,688.00
Other current financial assets
Total of other current financial assets 1,40,641.00
Total current financial assets 12,51,707.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 1,04,124.00
Total of other current assets 1,04,124.00
Total current assets 17,91,202.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 38,49,309.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 16,156.00
Other equity 34,03,955.00
Total equity attributable to owners of parent 34,20,111.00
Non controlling interest
Total equity 34,20,111.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 7,888.00
2 Other Financial Liabilities 18,094.00
Total of other non-current financial liabilities 25,982.00
Total non-current financial liabilities 25,982.00
Provisions, non-current 11,557.00
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
1 Other non-current liabilities 4,481.00
Total of other non-current liabilities 4,481.00
Total non-current liabilities 42,020.00
Current liabilities
Current financial liabilities
Borrowings, current 1,060.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 16,035.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,90,120.00
Total Trade payable 2,06,155.00
Other current financial liabilities
1 Lease Liabilities 3,549.00
2 Other current financial liabilities 69,661.00
Total of other current financial liabilities 73,210.00
Total current financial liabilities 2,80,425.00
Other current liabilities 13,530.00
1 Other current liabilities 13,530.00
Total of other current liabilities 13,530.00
Provisions, current 93,223.00
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 3,87,178.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 4,29,198.00
Total equity and liabilites 38,49,309.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss (309.00) (1,260.00)
Total Amount of items that will not be reclassified to profit and loss (309.00) (1,260.00)
2 Income tax relating to items that will not be reclassified to profit or loss (78.00) (317.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss (7,092.00) (18,291.00)
Total Amount of items that will be reclassified to profit and loss (7,092.00) (18,291.00)
4 Income tax relating to items that will be reclassified to profit or loss (1,785.00) (4,604.00)
5 Total Other comprehensive income (5,538.00) (14,630.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 4,63,594.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,930.00
Adjustments for decrease (increase) in inventories (74,659.00)
Adjustments for decrease (increase) in trade receivables, current 64,910.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (46,393.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 15,830.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 6,662.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 68,943.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (2,126.00)
Adjustments for dividend income 20,966.00
Adjustments for interest income 28,026.00
Adjustments for share-based payments 2,494.00
Adjustments for fair value losses (gains) (12,286.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (34,834.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 337.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (58,184.00)
Net cash flows from (used in) operations 4,05,410.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,22,241.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,83,169.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 22,770.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 501.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 936.00
Purchase of property, plant and equipment 78,069.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 4,405.00
Purchase of intangible assets 1,38,813.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 1,737.00
Cash advances and loans made to other parties 79,956.00
Cash receipts from repayment of advances and loans made to other parties 29,480.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 20,966.00
Interest received 27,585.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 1,04,065.00
Net cash flows from (used in) investing activities (1,34,409.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 4.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,060.00
Repayments of borrowings 0.00
Payments of lease liabilities 2,516.00
Dividends paid 1,29,240.00
Interest paid 1,498.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (1,32,190.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 16,570.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 36.00
Net increase (decrease) in cash and cash equivalents 16,606.00
Cash and cash equivalents cash flow statement at beginning of period 8,274.00
Cash and cash equivalents cash flow statement at end of period 24,880.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Walker Chandiok & Co LLP Yes 31-05-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Cipla Limited A S Kumar Director of subsidiary Any other transaction Professional Fees 651.00 Approved 163.00 0.00 0.00
2 Cipla Limited AMPIN Energy Green Eleven Private Limited Associate Any other transaction Electricity charges paid 1,200.00 Approved 645.00 0.00 0.00
3 Cipla Limited AMPIN Power Systems Private Limited Associate Any other transaction Electricity charges paid 2,000.00 Approved 1,127.00 0.00 0.00
4 Cipla Limited Aspergen Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 1,000.00 Approved 529.00 0.00 0.00
5 Cipla Limited Aspergen Inc. Holding-Subsidiary Sale of goods or services 5,000.00 Approved 393.00 0.00 0.00
6 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. (4.00) 0.00 0.00
7 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 10,213.00 0.00 0.00
8 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 182.00 0.00 0.00
9 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 433.00 0.00 0.00
10 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 9.00 0.00 0.00
11 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 702.00 0.00 0.00
12 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 8,716.00 0.00 0.00
13 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 153.00 0.00 0.00
14 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 110.00 0.00 0.00
15 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 255.00 0.00 0.00
16 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 184.00 0.00 0.00
17 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 6.00 0.00 0.00
18 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 454.00 0.00 0.00
19 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 443.00 0.00 0.00
20 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 473.00 0.00 0.00
21 Cipla Limited Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,328.00 0.00 0.00
22 Cipla Limited Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
23 Cipla Limited Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 813.00 0.00 0.00
24 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
25 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 902.00 0.00 0.00
26 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 6.00 0.00 0.00
27 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
28 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,062.00 0.00 0.00
29 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 101.00 0.00 0.00
30 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,462.00 0.00 0.00
31 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 9.00 0.00 0.00
32 Cipla Limited Cipla Europe NV Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 8,272.00 0.00 0.00
33 Cipla Limited Cipla Foundation The entity over which KMP or relative of KMP are able to exercise significant influence Any other transaction CSR and CER Contributions 11,000.00 Approved 5,310.00 0.00 0.00
34 Cipla Limited Cipla Gulf FZ – LLC Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 7.00 0.00 0.00
35 Cipla Limited Cipla Gulf FZ – LLC Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
36 Cipla Limited Cipla Gulf FZ – LLC Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 341.00 0.00 0.00
37 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 13.00 0.00 0.00
38 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,009.00 0.00 0.00
39 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Technical Know-How/Fees received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3.00 0.00 0.00
40 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,265.00 0.00 0.00
41 Cipla Limited Cipla Health Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,840.00 0.00 0.00
42 Cipla Limited Cipla Health Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,631.00 0.00 0.00
43 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 6.00 0.00 0.00
44 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 450.00 0.00 0.00
45 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
46 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 34.00 0.00 0.00
47 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 663.00 0.00 0.00
48 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 745.00 0.00 0.00
49 Cipla Limited Cipla Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Contribution to Gratuity Fund (Net) 41,000.00 Approved 23,475.00 0.00 0.00
50 Cipla Limited Cipla Limited Employees Provident Fund Post Employment Benefit Trust Any other transaction Contribution to Provident Fund 19,000.00 Approved 3,277.00 0.00 0.00
51 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3.00 0.00 0.00
52 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 582.00 0.00 0.00
53 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
54 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Reimbursement Charges Received 400.00 Approved 33.00 0.00 0.00
55 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Royalty Income 300.00 Approved 130.00 0.00 0.00
56 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Sale of goods or services 11,900.00 Approved 2,461.00 0.00 0.00
57 Cipla Limited Cipla Medpro Manufacturing Proprietary Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 100.00 Approved 1.00 0.00 0.00
58 Cipla Limited Cipla Medpro Manufacturing Proprietary Limited Holding-Subsidiary Sale of fixed assets 700.00 Approved 41.00 0.00 0.00
59 Cipla Limited Cipla Medpro Manufacturing Proprietary Limited Holding-Subsidiary Sale of goods or services 5,100.00 Approved 391.00 0.00 0.00
60 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Any other transaction Loan repaid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 8,257.00 0.00 0.00
61 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,967.00 0.00 0.00
62 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,899.00 0.00 0.00
63 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 325.00 0.00 0.00
64 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Rent Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 67.00 0.00 0.00
65 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,827.00 0.00 0.00
66 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 106.00 0.00 0.00
67 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 14,204.00 0.00 0.00
68 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,506.00 0.00 0.00
69 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 172.00 0.00 0.00
70 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Rent Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
71 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 181.00 0.00 0.00
72 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Loan 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 9,000.00 0.00 0.00
73 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Purchase of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 284.00 0.00 0.00
74 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 546.00 0.00 0.00
75 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 111.00 0.00 0.00
76 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 638.00 0.00 0.00
77 Cipla Limited Cipla Select Proprietary Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 4,153.00 0.00 0.00
78 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 19,722.00 0.00 0.00
79 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 27.00 0.00 0.00
80 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. (16,943.00) 0.00 0.00
81 Cipla Limited Cipla USA Inc. Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,072.00 0.00 0.00
82 Cipla Limited Cipla USA Inc. Holding-Subsidiary Loan 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 32,887.00 0.00 0.00
83 Cipla Limited Cipla USA Inc. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. (36.00) 0.00 0.00
84 Cipla Limited Cipla USA Inc. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 64,892.00 0.00 0.00
85 Cipla Limited CiplaRna GmbH Holding-Subsidiary Any other transaction Testing and Analysis Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,088.00 0.00 0.00
86 Cipla Limited Clean Max Auriga Power LLP Associate Any other transaction Electricity charges paid 1,100.00 Approved 467.00 0.00 0.00
87 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,249.00 0.00 0.00
88 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 7.00 0.00 0.00
89 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 49,194.00 0.00 0.00
90 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,650.00 0.00 0.00
91 Cipla Limited Geena Malhotra Director of subsidiary Any other transaction Professional Fees 200.00 Approved 41.00 0.00 0.00
92 Cipla Limited GoApptiv Private Limited Associate Any other transaction Reimbursement Charges Paid 1,500.00 Approved 288.00 0.00 0.00
93 Cipla Limited GoApptiv Private Limited Associate Purchase of goods or services 3,500.00 Approved 1,331.00 0.00 0.00
94 Cipla Limited GoApptiv Private Limited Associate Sale of goods or services 1,200.00 Approved 6.00 0.00 0.00
95 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Processing charges paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,592.00 0.00 0.00
96 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 753.00 0.00 0.00
97 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 36.00 0.00 0.00
98 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5,411.00 0.00 0.00
99 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 43.00 0.00 0.00
100 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,648.00 0.00 0.00
101 Cipla Limited Icaltech Innovations Private Limited Associate Any other transaction Reimbursement Charges Received 20.00 Approved 8.00 0.00 0.00
102 Cipla Limited Icaltech Innovations Private Limited Associate Purchase of goods or services 25.00 Approved 4.00 0.00 0.00
103 Cipla Limited Icaltech Innovations Private Limited Associate Sale of goods or services 30.00 Approved 8.00 0.00 0.00
104 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 170.00 0.00 0.00
105 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 106.00 0.00 0.00
106 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5,560.00 0.00 0.00
107 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 68.00 0.00 0.00
108 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Investment 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 913.00 0.00 0.00
109 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Loan 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,300.00 0.00 0.00
110 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,940.00 0.00 0.00
111 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 18.00 0.00 0.00
112 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Any other transaction Loan converted into Equity 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,300.00 0.00 0.00
113 Cipla Limited Jay Precision Pharmaceuticals Private Limited Holding-Subsidiary Purchase of goods or services 22,000.00 Approved 7,175.00 0.00 0.00
114 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Any other transaction Reimbursement Charges Paid 2,000.00 Approved 0.00 0.00 0.00
115 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of fixed assets 9,500.00 Approved 899.00 0.00 0.00
116 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of goods or services 500.00 Approved 44.00 0.00 0.00
117 Cipla Limited Kamil Hamied Non-executive Director Any other transaction Sitting Fees/Commission and Other Benefits 132.00 Approved 132.00 0.00 0.00
118 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Processing charges paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3,327.00 0.00 0.00
119 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Processing charges received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 210.00 0.00 0.00
120 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 16.00 0.00 0.00
121 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 98.00 0.00 0.00
122 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Purchase of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
123 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 17,183.00 0.00 0.00
124 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 7.00 0.00 0.00
125 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3,793.00 0.00 0.00
126 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Processing charges paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,373.00 0.00 0.00
127 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 17.00 0.00 0.00
128 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Purchase of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5.00 0.00 0.00
129 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 914.00 0.00 0.00
130 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3.00 0.00 0.00
131 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 32.00 0.00 0.00
132 Cipla Limited Medpro Pharmaceutica Proprietary Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 427.00 0.00 0.00
133 Cipla Limited Medpro Pharmaceutica Proprietary Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 27,604.00 0.00 0.00
134 Cipla Limited Mexicip, S.A. de C.V. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 671.00 0.00 0.00
135 Cipla Limited Mirren Proprietary Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
136 Cipla Limited Mirren Proprietary Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 22.00 0.00 0.00
137 Cipla Limited Sekhmet Technologies Private Limited Company in which a director or manager or his relative is a member or director Purchase of goods or services 500.00 Approved 57.00 0.00 0.00
138 Cipla Limited Signet Excipients Private Limited Related party of a subsidiary Any other transaction Freight charges paid 100.00 Approved 0.00 0.00 0.00
139 Cipla Limited Signet Excipients Private Limited Related party of a subsidiary Purchase of goods or services 10,000.00 Approved 976.00 0.00 0.00 Textual Information(1)
140 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 361.00 0.00 0.00
141 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 211.00 0.00 0.00
142 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Testing and Analysis Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 8,082.00 0.00 0.00
143 Cipla Limited Sitec Labs Limited Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 150.00 0.00 0.00
144 Cipla Limited Sitec Labs Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 277.00 0.00 0.00
145 Cipla Limited Sitec Labs Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 111.00 0.00 0.00
146 Cipla Limited Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of a subsidiary Sale of goods or services 5,000.00 Approved 706.00 0.00 0.00
147 Cipla Limited Stempeutics Research Private Limited Associate Any other transaction Reimbursement Charges Paid 200.00 Approved 36.00 0.00 0.00
148 Cipla Limited Stempeutics Research Private Limited Associate Purchase of goods or services 2,050.00 Approved 500.00 0.00 0.00
149 Cipla Limited Synpure Labs India Private Limited Related party of a subsidiary Purchase of goods or services 100.00 Approved 2.00 0.00 0.00
150 Cipla Limited Veritas Legal Firm in which director, manager or his relative is a partner Purchase of goods or services 400.00 Approved 150.00 0.00 0.00
151 Cipla Limited Wellspring Healthcare Private Limited Company in which a director or manager or his relative is a member or director Purchase of goods or services 50.00 Approved 12.00 0.00 0.00 Textual Information(2)
152 Cipla Limited Y K Hamied Non-executive Chairman Any other transaction Sitting Fees/Commission and Other Benefits 130.00 Approved 130.00 0.00 0.00
153 Cipla Limited Y K Hamied Non-executive Chairman Any other transaction Rent Received 0.00 Approved 0.00 0.00 0.00
154 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
155 Cipla Limited Achira Labs Private Limited Associate Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 3.00 3.00
156 Cipla Limited AMPIN Energy Green Eleven Private Limited Associate Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 200.00 277.00
157 Cipla Limited AMPIN Power Systems Private Limited Associate Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 0.00 284.00
158 Cipla Limited A S Kumar Director of subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 49.00 132.00
159 Cipla Limited Aspergen Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 461.00 1,228.00
160 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 6,468.00 3,745.00
161 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 1,161.00 443.00
162 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 5,924.00 5,000.00
163 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 (100.00) 125.00
164 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 2,337.00 2,011.00
165 Cipla Limited Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 2,414.00 3,081.00
166 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 4,694.00 3,305.00
167 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 362.00 382.00
168 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 10,691.00 10,073.00
169 Cipla Limited Cipla Gulf FZ – LLC Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 (1,076.00) 943.00
170 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 719.00 3,783.00
171 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 1,437.00 1,956.00
172 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 1,748.00 921.00
173 Cipla Limited Cipla Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 684.00 1,900.00
174 Cipla Limited Cipla Limited Employees Provident Fund Post Employment Benefit Trust Any other transaction Payable to Provident Fund Trust 0.00 Not Applicable 0.00 1,739.00 2,899.00
175 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 394.00 310.00
176 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 2,797.00 4,790.00
177 Cipla Limited Cipla Medpro Manufacturing Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 397.00 644.00
178 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 1,968.00 2,697.00
179 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Loan 0.00 Not Applicable 0.00 61,650.00 55,225.00 Loan 0 Repayable by 31st October 2029 Unsecured Working Capital Textual Information(3)
180 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 8,635.00 8,150.00
181 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Capital Creditors 0.00 Not Applicable 0.00 0.00 63.00
182 Cipla Limited CiplaRna GmbH Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 332.00 637.00
183 Cipla Limited Cipla Select Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 3,968.00 5,523.00
184 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 2,09,512.00 62,670.00
185 Cipla Limited Cipla USA Inc. Holding-Subsidiary Loan 0.00 Not Applicable 0.00 75,474.00 1,13,802.00 Loan 0 Repayable by 24th March 2028 Unsecured Working Capital Textual Information(4)
186 Cipla Limited Clean Max Auriga Power LLP Associate Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 29.00 61.00
187 Cipla Limited Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of a subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 1,883.00 1,016.00
188 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 16,491.00 34,971.00
189 Cipla Limited GoApptiv Private Limited Associate Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 735.00 128.00
190 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 2,732.00 1,543.00
191 Cipla Limited Icaltech Innovations Private Limited Associate Any other transaction Trade and Other receivable 0.00 Not Applicable 0.00 3.00 13.00
192 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 (1,471.00) 3,189.00
193 Cipla Limited Jay Precision Pharmaceuticals Private Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 1,925.00 1,822.00
194 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Any other transaction Capital Advances 0.00 Not applicable 0.00 0.00 1,322.00
195 Cipla Limited Kamil Hamied Non-executive Director Any other transaction Commission and Other Benefits payable 0.00 Not applicable 0.00 125.00 153.00
196 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 2,992.00 4,244.00
197 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 482.00 776.00
198 Cipla Limited Medpro Pharmaceutica Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 35,898.00 26,537.00
199 Cipla Limited Mexicip, S.A. de C.V. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 612.00 526.00
200 Cipla Limited Mirren Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 15.00 16.00
201 Cipla Limited Sekhmet Technologies Private Limited Company in which a director or manager or his relative is a member or director Any other transaction Trade and Other payable 0.00 Not applicable 0.00 53.00 17.00
202 Cipla Limited Signet Excipients Private Limited Related party of a subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 1,422.00 923.00
203 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not Applicable 0.00 552.00 1,049.00
204 Cipla Limited Sitec Labs Limited Holding-Subsidiary Loan 0.00 Not applicable 0.00 4,200.00 4,200.00 Loan 0 Repayable by 21st September 2027 Unsecured Working Capital Textual Information(5)
205 Cipla Limited Stempeutics Research Private Limited Associate Any other transaction Trade and Other payable 0.00 Not applicable 0.00 77.00 23.00
206 Cipla Limited Veritas Legal Firm in which director, manager or his relative is a partner Any other transaction Trade and Other payable 0.00 Not applicable 0.00 75.00 68.00
207 Cipla Limited Wellspring Healthcare Private Limited Company in which a director or manager or his relative is a member or director Any other transaction Trade and Other payable 0.00 Not applicable 0.00 6.00 7.00
208 Cipla Limited Y K Hamied Non-executive Chairman Any other transaction Commission and Other Benefits payable 0.00 Not applicable 0.00 125.00 153.00
209 Cipla Limited Cipla Foundation The entity over which KMP or relative of KMP are able to exercise significant influence Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 0.00 509.00
210 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 (8.00) 2,474.00
211 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Loan 0.00 Not applicable 0.00 0.00 9,000.00 Loan 7.2500 Repayable by 6th November, 2030 Unsecured Working Capital
212 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 0.00 72.00
213 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Loan 0.00 Not applicable 0.00 0.00 1,459.00 Loan 7.600 Repayable by 30th August 2032 Unsecured Working Capital
214 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 (318.00) 54.00
215 Cipla Limited Geena Malhotra Director of subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 33.00 0.00
216 Cipla Limited Synpure Labs India Private Limited Related party of a subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 0.00 0.00
217 Cipla Digital Health Limited Cipla Digital Health Limited Gratuity Trust Post Employment Benefit Trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 35.00 0.00 0.00
218 Jay Precision Pharmaceuticals Private Limited Cipla Foundation Related Party of the listed entity Any other transaction CSR Contribution 0.00 Not Applicable 58.00 0.00 0.00
219 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Purchase of fixed assets 4,000.00 Approved 362.00 0.00 0.00
220 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Rent received 100.00 Approved 8.00 0.00 0.00
221 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Sale of goods or services 100.00 Approved 4.00 0.00 0.00
222 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Purchase of goods or services 200.00 Approved 8.00 0.00 0.00
223 Jay Precision Pharmaceuticals Private Limited Medispray Laboratories Private Limited Subsidiaries Sale of goods or services 4,500.00 Approved 447.00 0.00 0.00
224 Jay Precision Pharmaceuticals Private Limited Cipla Maroc SA Subsidiaries Sale of goods or services 200.00 Approved 43.00 0.00 0.00
225 Jay Precision Pharmaceuticals Private Limited Ampin Energy C&I Eighteen Private Limited Associate Any other transaction Electricity charges paid 200.00 Approved 148.00 0.00 0.00
226 Meditab Specialities Limited Cipla Foundation Related Party of the listed entity Any other transaction CSR Contribution 0.00 Not Applicable 9.00 0.00 0.00
227 Meditab Specialities Limited Signet Excipients Private Limited Related Party of a Subsidary Purchase of goods or services 200.00 Approved 4.00 0.00 0.00
228 Meditab Specialities Limited Meditab Specialities Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Contribution to Gratuity Fund 600.00 Approved 435.00 0.00 0.00
229 Medispray Laboratories Private Limited Cipla Maroc SA Subsidiaries Sale of goods or services 5,000.00 Approved 796.00 0.00 0.00
230 Medispray Laboratories Private Limited Meditab Specialities Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
231 Medispray Laboratories Private Limited Meditab Specialities Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 7.00 0.00 0.00
232 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related Party of a Subsidary Purchase of goods or services 1,000.00 Approved 13.00 0.00 0.00
233 Medispray Laboratories Private Limited Signet Excipients Private Limited Related Party of a Subsidary Purchase of goods or services 500.00 Approved 72.00 0.00 0.00 Textual Information(6)
234 Medispray Laboratories Private Limited Cipla Foundation Related Party of the listed entity Any other transaction CSR Contribution 0.00 Not Applicable 106.00 0.00 0.00
235 Medispray Laboratories Private Limited Medispray Laboratories Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 2,025.00 0.00 0.00
236 Goldencross Pharma Limited Cipla Health Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 402.00 0.00 0.00
237 Goldencross Pharma Limited Cipla Foundation Related Party of the listed entity Any other transaction CSR Contribution 0.00 Not Applicable 9.00 0.00 0.00
238 Sitec Labs Limited Cipla USA Inc. Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 8.00 0.00 0.00
239 Sitec Labs Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 3.00 0.00 0.00
240 Sitec Labs Limited Meditab Specialities Limited Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
241 Sitec Labs Limited InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
242 Sitec Labs Limited Cipla Foundation Related Party of the listed entity Any other transaction CSR Contribution 0.00 Not Applicable 20.00 0.00 0.00
243 Sitec Labs Limited Sitec Labs Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Contribution to Gratuity Fund 1,500.00 Approved 786.00 0.00 0.00
244 Cipla Medpro Botswana Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 0.00
245 Cipla Health Limited Cipla Pharma and Life Sciences Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 767.00 0.00 0.00
246 Cipla Health Limited Cipla Foundation Related Party of the listed entity Any other transaction CSR Contribution 0.00 Not Applicable 149.00 0.00 0.00
247 Cipla Health Limited Signet Excipients Private Limited Private company in which a director/relative is a member/director Purchase of goods or services 1,200.00 Approved 155.00 0.00 0.00 Textual Information(7)
248 Cipla Health Limited Cipla Health Limited Employees Gratuity Scheme Post employment benefit trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 350.00 0.00 0.00
249 Cipla Pharma and Life Sciences Limited GoApptiv Private Limited Associate of listed entity Purchase of goods or services 200.00 Approved (106.00) 0.00 0.00
250 Cipla Pharma and Life Sciences Limited Cipla Foundation Related Party of the listed entity Any other transaction CSR Contribution 0.00 Not Applicable 323.00 0.00 0.00
251 Cipla Pharma and Life Sciences Limited Cipla Pharma and Life Sciences Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 409.00 0.00 0.00
252 Meditab Holdings Limited Cipla Kenya Limited Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 50.00 0.00 0.00
253 Cipla USA Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 582.00 0.00 0.00
254 Cipla USA Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 64.00 0.00 0.00
255 Cipla USA Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 118.00 0.00 0.00
256 Cipla USA Inc. Aspergen Inc. Subsidiaries Sale of goods or services 5,000.00 Approved 53.00 0.00 0.00
257 Cipla USA Inc. Aspergen Inc. Subsidiaries Any other transaction Reimbursement charges received 500.00 Approved 57.00 0.00 0.00
258 Actor Pharma Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 274.00 0.00 0.00
259 Actor Pharma Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 1,183.00 0.00 0.00
260 Cipla-Medpro Distribution Centre Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 4,531.00 0.00 0.00
261 Cipla Medpro Manufacturing Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Sale of goods or services 60,000.00 Approved 25,331.00 0.00 0.00
262 Cipla Medpro Manufacturing Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Sale of goods or services 2,000.00 Approved 901.00 0.00 0.00
263 Cipla Medpro Manufacturing Proprietary Limited The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction Donation paid 1,500.00 Approved 492.00 0.00 0.00
264 Cipla Medpro South Africa Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 2,000.00 Approved 83.00 0.00 0.00
265 Cipla Medpro South Africa Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Any other transaction Royalty Income 5,000.00 Approved 2,307.00 0.00 0.00
266 Cipla Medpro South Africa Proprietary Limited Brandmed Proprietary Limited Associate Interest received 0.00 Not Applicable 100.00 0.00 0.00
267 Cipla Medpro South Africa Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,791.00 0.00 0.00
268 Cipla Medpro South Africa Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Loan given 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5,404.00 0.00 0.00
269 Cipla Select Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 106.00 0.00 0.00
270 Cipla-Medpro Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Royalty Income 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 1,272.00 0.00 0.00
271 Cipla-Medpro Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Royalty Income 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 121.00 0.00 0.00
272 Medpro Pharmaceutica Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 156.00 0.00 0.00
273 Medpro Pharmaceutica Proprietary Limited Cipla Kenya Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 29.00 0.00 0.00
274 Medpro Pharmaceutica Proprietary Limited Cipla-Medpro Distribution Centre Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 630.00 0.00 0.00
275 Medpro Pharmaceutica Proprietary Limited The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction Donation paid 1,500.00 Approved 40.00 0.00 0.00
276 Medpro Pharmaceutica Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 310.00 0.00 0.00
277 Medpro Pharmaceutica Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 2,315.00 0.00 0.00
278 Medpro Pharmaceutica Proprietary Limited Cipla Medpro South Africa Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 775.00 0.00 0.00
279 Medpro Pharmaceutica Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 5,000.00 Approved 1,878.00 0.00 0.00
280 Medpro Pharmaceutica Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Any other transaction Reimbursement charges paid 8,581.00 Approved 4,387.00 0.00 0.00
281 Medpro Pharmaceutica Proprietary Limited Mirren Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 19.00 0.00 0.00
282 Medpro Pharmaceutica Proprietary Limited Cipla Kenya Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 23.00 0.00 0.00
283 Medpro Pharmaceutica Proprietary Limited Cipla-Medpro Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 330.00 0.00 0.00
284 Mirren Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 6,647.00 0.00 0.00
285 Mirren Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Sale of goods or services 0.00 Not Applicable 4.00 0.00 0.00
286 Meditab Holdings Limited Cipla Kenya Limited Subsidiaries Any other transaction Repayment of loan received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 903.00 0.00 0.00
287 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 8,012.00 0.00 0.00
288 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 17,184.00 0.00 0.00
289 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 5,073.00 0.00 0.00
290 InvaGen Pharmaceuticals Inc. Exelan Pharmaceuticals Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 13,267.00 0.00 0.00
291 InvaGen Pharmaceuticals Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 8,035.00 0.00 0.00
292 InvaGen Pharmaceuticals Inc. Cipla Therapeutics Inc. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
293 Cipla Europe NV CiplaRna GmbH Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 307.00 0.00 0.00
294 Cipla Europe NV CiplaRna GmbH Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 207.00 0.00 0.00
295 Cipla (EU) Limited Cipla Europe NV Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 231.00 0.00 0.00
296 Cipla (EU) Limited Cipla Gulf FZ-LLC Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 34.00 0.00 0.00
297 Cipla (EU) Limited Cipla Australia Pty Limited Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 11.00 0.00 0.00
298 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 335.00 0.00 0.00
299 Cipla (EU) Limited Mexicip, S.A. de C.V. Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 22.00 0.00 0.00
300 Cipla (EU) Limited Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Subsidiaries Investment 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,708.00 0.00 0.00
301 Cipla (EU) Limited Cipla Middle East Company Subsidiaries Investment 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 362.00 0.00 0.00
302 Cipla Gulf FZ-LLC Cipla Australia Pty Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
303 Cipla Gulf FZ-LLC Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 11.00 0.00 0.00
304 Cipla Medpro Manufacturing Proprietary Limited Signet Excipients Private Limited Related party of a subsidiary Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 3.00 0.00
305 Cipla (Jiangsu) Pharmaceutical Co., Ltd. Cipla USA Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 9,334.00 0.00 0.00
306 Cipla (China) Pharmaceutical Co., Ltd. Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 113.00 0.00 0.00
307 Cipla (China) Pharmaceutical Co., Ltd. Shanghai Sage Business Consulting Co Ltd Entity related to KMP Any other transaction Professional Fees paid 500.00 Approved 115.00 0.00 0.00
308 Cipla Europe NV CiplaRna GmbH Subsidiaries Sale of fixed assets 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 230.00 0.00 0.00
309 Cipla Holding B.V. Cipla (EU) Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 507.00 0.00 0.00
310 Cipla Holding B.V. Cipla Europe NV Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 483.00 0.00 0.00
311 Cipla (EU) Limited Mexicip, S.A. de C.V. Subsidiaries Any other transaction Repayment of loan received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 226.00 0.00 0.00
312 Cipla Maroc SA Societe Marocaine De Cooperation Pharmaceutique (Cooper) Investing Company Purchase of goods or services 4,000.00 Approved 533.00 0.00 0.00
313 Cipla Maroc SA Societe Marocaine De Cooperation Pharmaceutique (Cooper) Investing Company Sale of goods or services 26,569.00 Approved 14,334.00 0.00 0.00
314 Cipla Medpro Manufacturing Proprietary Limited Signet Excipients Private Limited Related Party of a Subsidary Purchase of goods or services 1,500.00 Approved 116.00 0.00 0.00 Textual Information(8)
315 Aspergen Inc. Kemwell Biopharma Private Limited Private company in which a director/relative is a member/director Purchase of goods or services 15,000.00 Approved 3,288.00 0.00 0.00
316 Aspergen Inc. Kemwell Biopharma Private Limited Private company in which a director/relative is a member/director Any other transaction Reimbursement Charges Paid 3,000.00 Approved 1,417.00 0.00 0.00
317 Medispray Laboratories Private Limited Meditab Specialities Limited Subsidiaries Sale of fixed assets 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
318 Meditab Specialities Limited Medispray Laboratories Private Limited Subsidiaries Investment 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5,700.00 0.00 0.00
319 Meditab Specialities Limited Sitec Labs Limited Subsidiaries Investment 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 6,498.00 0.00 0.00
320 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related Party of a Subsidary Any other transaction Capital Advance 10,000.00 Approved 1,655.00 0.00 0.00
321 Goldencross Pharma Limited Goldencross Pharma Limited Employees Group Gratuity Fund Post Employment Benefit Trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 716.00 0.00 0.00
322 Cipla (EU) Limited Cipla Australia Pty Limited Subsidiaries Any other transaction Repayment of loan received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,532.00 0.00 0.00
323 Cipla (EU) Limited Cipla Gulf FZ-LLC Subsidiaries Any other transaction Repayment of loan received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,805.00 0.00 0.00
324 Cipla (EU) Limited CiplaRna GmbH Subsidiaries Investment 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 452.00 0.00 0.00
325 Cipla Pharmaceuticals Limited Cipla Foundation Related Party of the listed entity Any other transaction CER Contribution 560.00 Approved 171.00 0.00 0.00
326 Cipla Digital Health Limited Cipla Digital Health Limited Gratuity Trust Post Employment Benefit Trust Any other transaction Receivable from Gratuity Trust 0.00 Not Applicable 0.00 (15.00) 5.00
327 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Capital Advance 0.00 Not Applicable 0.00 (432.00) 399.00
328 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1.00 5.00
329 Jay Precision Pharmaceuticals Private Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 141.00 49.00
330 Jay Precision Pharmaceuticals Private Limited Cipla Maroc SA Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 21.00 45.00
331 Jay Precision Pharmaceuticals Private Limited Jay Precision Pharmaceuticals Employees Group Gratuity Trust Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 19.00 43.00
332 Meditab Specialities Limited Signet Excipients Private Limited Related Party of a Subsidary Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 3.00 0.00
333 Meditab Specialities Limited Meditab Specialities Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 247.00 24.00
334 Medispray Laboratories Private Limited Cipla Maroc SA Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1,591.00 838.00
335 Medispray Laboratories Private Limited Meditab Specialities Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1.00 3.00
336 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related Party of a Subsidary Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 13.00 0.00
337 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related Party of a Subsidary Any other transaction Capital Advance 0.00 Not Applicable 0.00 0.00 2,006.00
338 Medispray Laboratories Private Limited Signet Excipients Private Limited Related Party of a Subsidary Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 49.00 29.00
339 Medispray Laboratories Private Limited Medispray Laboratories Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 1,091.00 123.00
340 Goldencross Pharma Limited Jay Precision Pharmaceuticals Private Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 28.00 0.00
341 Goldencross Pharma Limited Cipla Health Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 95.00 0.00
342 Goldencross Pharma Limited Goldencross Pharma Limited Employees Group Gratuity Fund Post Employment Benefit Trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 353.00 16.00
343 Sitec Labs Limited Cipla USA Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 6.00 3.00
344 Sitec Labs Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 5.00 3.00
345 Sitec Labs Limited Meditab Specialities Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 0.00
346 Sitec Labs Limited Cipla Health Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 0.00
347 Sitec Labs Limited InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 36.00 0.00
348 Sitec Labs Limited Sitec Labs Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 707.00 636.00
349 Cipla Health Limited Cipla Pharma and Life Sciences Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 169.00 901.00
350 Cipla Health Limited Signet Excipients Private Limited Private company in which a director/relative is a member/director Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 290.00 0.00
351 Cipla Health Limited Cipla Health Limited Employees Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 146.00 260.00
352 Cipla Pharma and Life Sciences Limited GoApptiv Private Limited Associate of listed entity Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 156.00 18.00
353 Cipla Pharma and Life Sciences Limited Cipla Pharma and Life Sciences Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Receivable from Gratuity Trust 0.00 Not Applicable 0.00 (211.00) 51.00
354 Actor Pharma Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 2,361.00 1,753.00
355 Actor Pharma Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 2,204.00 2,326.00
356 Cipla-Medpro Distribution Centre Proprietary Limited Cipla Kenya Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 27.00 0.00
357 Cipla Medpro Manufacturing Proprietary Limited Cipla Empowerment Trust Entities over which the company is able to exercise significant influence/Control Any other transaction Advance 0.00 Not Applicable 0.00 0.00 0.00
358 Cipla Medpro Manufacturing Proprietary Limited Cipla Empowerment Trust Entities over which the company is able to exercise significant influence/Control Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 8.00
359 Cipla Medpro Manufacturing Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 31,527.00 48,062.00
360 Cipla Medpro Manufacturing Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 469.00 1,729.00
361 Cipla Medpro South Africa Proprietary Limited Brandmed Proprietary Limited Associate Loan 0.00 Not Applicable 0.00 2,301.00 2,575.00 Loan 0 Repayment to start from 31 March 2025 to 31 March 2028 Unsecured Working Capital Textual Information(9)
362 Cipla Medpro South Africa Proprietary Limited Cipla-Medpro Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 221.00 0.00
363 Cipla Medpro South Africa Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1,322.00 4,154.00
364 Cipla Medpro South Africa Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Loan 0.00 Not Applicable 0.00 40,073.00 48,598.00 Loan 0 Repayament starts with 31 March 2026 to Oct 2029 Unsecured Working Capital Textual Information(10)
365 Cipla Select Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 3.00 69.00
366 Cipla-Medpro Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 269.00 194.00
367 Medpro Pharmaceutica Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 17,610.00 57,304.00
368 Medpro Pharmaceutica Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 162.00 174.00
369 Medpro Pharmaceutica Proprietary Limited Cipla Medpro South Africa Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 24,382.00 37,188.00
370 Medpro Pharmaceutica Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 70.00 2,908.00
371 Medpro Pharmaceutica Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 3,491.00 1,828.00
372 Medpro Pharmaceutica Proprietary Limited Cipla Kenya Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 2,860.00 3,127.00
373 Medpro Pharmaceutica Proprietary Limited Cipla-Medpro Distribution Centre Proprietary Limited Subsidiaries Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 1,009.00 1,082.00
374 Medpro Pharmaceutica Proprietary Limited Cipla-Medpro Proprietary Limited Subsidiaries Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 122.00 193.00
375 Medpro Pharmaceutica Proprietary Limited Mirren Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 5,719.00 5,975.00
376 Mirren Proprietary Limited Cipla Medpro Manufacturing Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 104.00 116.00
377 Mirren Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1,564.00 3,137.00
378 Meditab Holdings Limited Cipla Kenya Limited Subsidiaries Loan 0.00 Not Applicable 0.00 2,400.00 1,655.00 Loan 6.00 Repayable on Demand Unsecured Working Capital
379 Cipla USA Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1.00 0.00
380 Cipla USA Inc. Aspergen Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 42.00 144.00
381 Cipla USA Inc. Cipla Therapeutics Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 148.00 0.00
382 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 10,703.00 721.00
383 InvaGen Pharmaceuticals Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 3,935.00 4,295.00
384 InvaGen Pharmaceuticals Inc. Cipla Therapeutics Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 2.00
385 Aspergen Inc. Kemwell Biopharma Private Limited Private company in which a director/relative is a member/director Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 2,766.00 7,752.00
386 Cipla Maroc SA Societe Marocaine De Cooperation Pharmaceutique (Cooper) Investing Company Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 7,069.00 7,326.00
387 Cipla Maroc SA Societe Marocaine De Cooperation Pharmaceutique (Cooper) Investing Company Any other transaction Interest Payable 0.00 Not Applicable 0.00 64.00 62.00
388 Cipla Australia Pty Limited Cipla Gulf FZ-LLC Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 859.00 951.00
389 Cipla Europe NV CiplaRna GmbH Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 179.00 1,002.00
390 Cipla (EU) Limited Cipla Europe NV Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 2,603.00 507.00
391 Cipla (EU) Limited Cipla Gulf FZ-LLC Subsidiaries Loan 0.00 Not Applicable 0.00 1,776.00 0.00 Loan 5.500 5 Unsecured Working Capital
392 Cipla (EU) Limited Cipla Australia Pty Limited Subsidiaries Any other transaction Interest receivable 0.00 Not Applicable 0.00 61.00 0.00
393 Cipla (EU) Limited Cipla Australia Pty Limited Subsidiaries Loan 0.00 Not Applicable 0.00 1,506.00 0.00 Loan 2.800 4 to 6 Unsecured Working Capital
394 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Loan 0.00 Not Applicable 0.00 11,099.00 11,854.00 Loan 0 1 Unsecured Working Capital Textual Information(11)
395 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Any other transaction Interest Receivable 0.00 Not Applicable 0.00 1,959.00 2,445.00
396 Cipla (EU) Limited Mexicip, S.A. de C.V. Subsidiaries Loan 0.00 Not Applicable 0.00 577.00 379.00 Loan 8.00 2 Unsecured Working Capital
397 Cipla (EU) Limited Cipla Maroc SA Subsidiaries Any other transaction Dividend Receivable 0.00 Not Applicable 0.00 1,631.00 0.00
398 Cipla Holding B.V. Cipla Europe NV Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 985.00 441.00
399 Cipla Holding B.V. Cipla (EU) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1,109.00 490.00
400 Cipla Gulf FZ-LLC Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1,147.00 224.00
401 Cipla (Jiangsu) Pharmaceutical Co., Ltd. Cipla (EU) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 23.00 0.00
402 Cipla (Jiangsu) Pharmaceutical Co., Ltd. Cipla USA Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 5,221.00 9,606.00
403 Cipla (China) Pharmaceutical Co., Ltd Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 109.00 60.00
404 Cipla (China) Pharmaceutical Co., Ltd Shanghai Sage Business Consulting Co Ltd Entity related to KMP Any other transaction Trade and Other Payable 0.00 Not Applicable 0.00 57.00 61.00
405 Cipla (EU) Limited CiplaRna GmbH Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 12.00 13.00
Total value of transaction during the reporting period 5,64,784.00



Text Block

Textual Information(1) Additionally, during FY 25, transaction of INR 90.78 cr was entered with Cipla Limited. Additionally, during FY 25, transaction of INR 6.1 cr was entered with Goldencross Pharma Limited.
Textual Information(2) Additionally, during FY 25, transaction of INR 0.15 cr was entered.
Textual Information(3) Interest Rate: 250 bps higher than 3 months JIBAR rate
Textual Information(4) Interest rate: Term SOFR + 150 bps
Textual Information(5) Inetrest rate: 6.5%-7.5%
Textual Information(6) Additionally, during FY 25, transaction of INR 1.85 cr was entered.
Textual Information(7) Additionally, during FY 25, transaction of INR 2.48 cr was entered.
Textual Information(8) Additionally, during FY 25, transaction of INR 6.15 cr was entered.
Textual Information(9) Interets Rate : South African prime rate less 1.75%
Textual Information(10) Interets rate: 250 bps higher than 3 months JIBAR rate capped at the prime lending rate in South Africa
Textual Information(11) Interest Rate: 4% to 6%